MetLife Investment Management LLC Has $184,000 Stock Position in Revance Therapeutics, Inc. (NASDAQ:RVNC)

MetLife Investment Management LLC boosted its holdings in Revance Therapeutics, Inc. (NASDAQ:RVNC) by 7.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 60,514 shares of the biopharmaceutical company’s stock after purchasing an additional 4,235 shares during the quarter. MetLife Investment Management LLC owned about 0.06% of Revance Therapeutics worth $184,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Slotnik Capital LLC bought a new stake in shares of Revance Therapeutics in the 4th quarter valued at $2,042,000. Candriam S.C.A. bought a new stake in Revance Therapeutics in the fourth quarter valued at $909,000. FNY Investment Advisers LLC raised its holdings in shares of Revance Therapeutics by 160.4% during the fourth quarter. FNY Investment Advisers LLC now owns 477,823 shares of the biopharmaceutical company’s stock valued at $1,452,000 after purchasing an additional 294,323 shares during the period. Alliancebernstein L.P. boosted its position in shares of Revance Therapeutics by 7.3% during the 4th quarter. Alliancebernstein L.P. now owns 3,497,112 shares of the biopharmaceutical company’s stock worth $10,631,000 after purchasing an additional 236,641 shares in the last quarter. Finally, GABELLI & Co INVESTMENT ADVISERS INC. grew its stake in shares of Revance Therapeutics by 26.0% in the 4th quarter. GABELLI & Co INVESTMENT ADVISERS INC. now owns 1,058,500 shares of the biopharmaceutical company’s stock valued at $3,218,000 after buying an additional 218,700 shares during the period. 97.70% of the stock is owned by institutional investors and hedge funds.

Revance Therapeutics Stock Performance

Shares of NASDAQ:RVNC opened at $3.65 on Friday. Revance Therapeutics, Inc. has a 1-year low of $2.30 and a 1-year high of $6.65. The stock has a market cap of $381.02 million, a PE ratio of -1.89 and a beta of 0.90. The stock’s fifty day simple moving average is $3.65 and its two-hundred day simple moving average is $3.76.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on RVNC. StockNews.com assumed coverage on Revance Therapeutics in a research note on Monday. They set a “hold” rating on the stock. Needham & Company LLC reaffirmed a “hold” rating on shares of Revance Therapeutics in a research report on Friday, January 17th. Nine research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat, Revance Therapeutics has an average rating of “Hold” and an average price target of $8.39.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.